Live Breaking News & Updates on Administration Section Of The Prescribing Information|Page 1

Share this article
Share this article
TITUSVILLE, N.J., Jan. 21, 2021 /PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved CABENUVA (consisting of Janssen s rilpivirine and ViiV Healthcare s cabotegravir), the first and only once-monthly, long-acting regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. The novel regimen was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen s 25-year commitment to make HIV history. In the U.S., ViiV Healthcare is the marketing authorization holder for CABENUVA.
CABENUVA is indicated as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen, with no history of treatment failure, and with no known or susp ....

United States , Paul Stoffels , Susan Swindells , Mathai Mammen , Health Canada On , University Of Nebraska Medical Center , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , Janssen Research Development , Janssen Sciences Ireland , Administration Section Of The Prescribing Information , Janssen Sciences Ireland Unlimited Company , None Of The Janssen Pharmaceutical Companies , Department Of Internal Medicine , Drug Administration , European Commission , Exchange Commission , Companies Of Johnson , Viiv Healthcare , Vice Chairman , Executive Committee , Chief Scientific Officer , Antiretroviral Therapy , Long Acting Suppression , First Long Acting Injectable Regimen , Treatment Difference ,